Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Free Cash Flow (2016 - 2025)

ImmunityBio (IBRX) has disclosed Free Cash Flow for 12 consecutive years, with -$71.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 21.47% to -$71.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$308.7 million, a 22.45% increase, with the full-year FY2025 number at -$308.7 million, up 22.45% from a year prior.
  • Free Cash Flow was -$71.2 million for Q4 2025 at ImmunityBio, down from -$69.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$67.6 million in Q1 2021 to a low of -$126.4 million in Q3 2022.
  • A 5-year average of -$89.9 million and a median of -$87.7 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: tumbled 118.29% in 2021, then surged 35.63% in 2023.
  • ImmunityBio's Free Cash Flow stood at -$82.0 million in 2021, then crashed by 33.66% to -$109.7 million in 2022, then rose by 4.82% to -$104.4 million in 2023, then grew by 13.13% to -$90.7 million in 2024, then grew by 21.47% to -$71.2 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Free Cash Flow are -$71.2 million (Q4 2025), -$69.7 million (Q3 2025), and -$80.8 million (Q2 2025).